Drugs / Merestinib
Merestinib
also known as
LY2801653
Small molecule targets AXL, DDR1, FLT3, MERTK, MET, MKNK1, MST1R, NTRK1, ROS1, TEK via inhibition
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT03292536 | Jan 2018 → Jun 2019 | bone neoplasm, breast cancer | University of Utah | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03125239 | Aug 2017 → Jun 2020 | acute myeloid leukemia | Jacqueline Garcia, MD | Completed | No outcome recorded |
| Phase 1 | NCT03027284 | Feb 2017 → Jun 2019 | cholangiocarcinoma, gallbladder carcinoma, metastatic malignant neoplasm, non-Hodgkin lymphoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02745769 | Oct 2016 → Nov 2018 | colorectal cancer, mantle cell lymphoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02791334 | Jun 2016 → May 2020 | cutaneous melanoma, hormone receptor-positive breast cancer, malignant pancreatic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02779738 | May → Aug 2016 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02370485 | Feb → May 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01981408 | Nov → Dec 2013 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01285037 | Sep 2009 → Jul 2017 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT02920996 | Nov 2016 → Oct 2021 | non-small cell lung carcinoma | Dana-Farber Cancer Institute | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02711553 | May 2016 → Feb 2018 overdue | biliary tract cancer, metastatic malignant neoplasm | Eli Lilly and Company | Active not recruiting | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2013-04-10 | Eli Lilly and Company | Results Lilly Debuts Early Oncology Pipeline Data At AACR Annual Meeting lilly.com ↗
The data suggest that inhibitors of receptor tyrosine kinases and their signaling pathways―such as LY2801653―may merit clinical evaluation in patients with cholangiocarcinoma. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-04-10 | Eli Lilly and Company | Lilly Debuts Early Oncology Pipeline Data At AACR Annual Meeting lilly.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Merestinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02779738 ↗ |
| Known as | LY2801653 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01285037 ↗ |
| Action | Inhibit | “We report here preclinical development of a potent, orally bioavailable, small-molecule inhibitor LY2801653 targeting MET kinase.” PMID 23275061 ↗ Dec 2012 |
| Modality | Small molecule | “We report here preclinical development of a potent, orally bioavailable, small-molecule inhibitor LY2801653 targeting MET kinase.” PMID 23275061 ↗ Dec 2012 |
| Route | Oral | “LY2801653 given orally once daily during 28-day cycles.” NCT01285037 ↗ |
| Target | MET | “We report here preclinical development of a potent, orally bioavailable, small-molecule inhibitor LY2801653 targeting MET kinase.” PMID 23275061 ↗ Dec 2012 |